Tan Zhaoyi, Ge Chun, Feng Dong, Xu Chen, Cao Bei, Xie Yuan, Zhou Honghao, Wang Guangji, Aa Jiye
Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines (Z.T., D.F., C.X., Y.X., G.W.) and Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy (C.G.), China Pharmaceutical University, Nanjing, China; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China (C.G.); Nanjing Southern Pharmaceutical Technology Co. Ltd., Nanjing, China (D.F.); Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China (B.C.); and Pharmacogenetics Research Institute, Xiang-Ya School of Medicine, Central South University, Changsha, China (H.Z.).
Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines (Z.T., D.F., C.X., Y.X., G.W.) and Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy (C.G.), China Pharmaceutical University, Nanjing, China; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China (C.G.); Nanjing Southern Pharmaceutical Technology Co. Ltd., Nanjing, China (D.F.); Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China (B.C.); and Pharmacogenetics Research Institute, Xiang-Ya School of Medicine, Central South University, Changsha, China (H.Z.)
Drug Metab Dispos. 2021 Nov;49(11):985-994. doi: 10.1124/dmd.121.000571. Epub 2021 Aug 30.
Drug resistance of cancer cells is associated with redox homeostasis. The mechanism of acquired resistance of cancer cells to antitumor drugs is not well understood. Our previous studies revealed that drug resistance and highly expressed P-glycoprotein (P-gp) of MCF-7 breast cancer cells was dependent on intracellular redox homeostasis and declined capacity for scavenging reactive oxygen species (ROS). Recently, we observed that, unlike nontumorigenic cells MCF-10A, three tumorigenic breast cancer cells (MCF-7S, BT474, MDA-MB-231) reprogrammed their metabolism, highly expressed cystathionine--lyase (CTH), and acquired a particular specialty to use methionine (Met) to synthesize glutathione (GSH) through the transsulfuration pathway. Interestingly, doxorubicin (adriamycin) further reprogrammed metabolism of MCF-7 cells sensitive to adriamycin (MCF-7S) and induced them to be another MCF-7 cell line resistant to adriamycin (MCF-7R) with dramatically downregulated CTH. The two MCF-7 cell lines showed distinctly different phenotypes in terms of intracellular GSH, ROS levels, expression and activity of P-gp and CTH, and drug resistance. We showed that CTH modulation or the methionine supply brought about the interconversion between MCF-7S and MCF-7R. Methionine deprivation or CTH silencing induced a resistant MCF-7R and lowered paclitaxel activity, yet methionine supplementation or CTH overexpression reversed the above effects, induced a sensitive phenotype of MCF-7S, and significantly increased the cytotoxicity of paclitaxel both in vitro and in vivo. Interleukin-6 (IL-6)/signal transducer and activator of transcription-3 (STAT3) initiated CTH expression and activity, and the effect on the resistant phenotype was exclusively dependent on CTH and ROS. This study suggests that the IL-6/STAT3/CTH axis plays a key role in the transformation between sensitive and resistant MCF-7 cells. SIGNIFICANCE STATEMENT: Cystathionine γ-lyase (CTH) plays a key role in transformation between the sensitive and resistant phenotypes of MCF-7 cells and is dependent on the interleukin-6 (IL-6)/signal transducer and activator of transcription-3 (STAT3) signaling axis. Modulation of the transsulfuration pathway on CTH or IL-6/STAT3 or methionine supplementation is beneficial for reversing the resistance of MCF-7 cells, which indicates a clinical translation potential.
癌细胞的耐药性与氧化还原稳态相关。癌细胞对抗肿瘤药物获得性耐药的机制尚未完全明确。我们之前的研究表明,MCF - 7乳腺癌细胞的耐药性及高表达的P - 糖蛋白(P - gp)依赖于细胞内氧化还原稳态以及清除活性氧(ROS)能力的下降。最近,我们观察到,与非致瘤性细胞MCF - 10A不同,三种致瘤性乳腺癌细胞(MCF - 7S、BT474、MDA - MB - 231)重新编程了它们的代谢,高表达胱硫醚 -γ- 裂解酶(CTH),并获得了一种特殊特性,即通过转硫途径利用蛋氨酸(Met)合成谷胱甘肽(GSH)。有趣的是,阿霉素进一步重新编程了对阿霉素敏感的MCF - 7细胞(MCF - 7S)的代谢,并诱导它们成为另一种对阿霉素耐药的MCF - 7细胞系(MCF - 7R),同时CTH显著下调。这两种MCF - 7细胞系在细胞内GSH、ROS水平、P - gp和CTH的表达及活性以及耐药性方面表现出明显不同的表型。我们发现CTH调节或蛋氨酸供应导致了MCF - 7S和MCF - 7R之间的相互转化。蛋氨酸剥夺或CTH沉默诱导产生耐药的MCF - 7R并降低紫杉醇活性,而蛋氨酸补充或CTH过表达则逆转上述效应,诱导出MCF - 7S的敏感表型,并在体外和体内均显著增加紫杉醇的细胞毒性。白细胞介素 - 6(IL - 6)/信号转导及转录激活因子3(STAT3)启动CTH的表达和活性,并且对耐药表型的影响完全依赖于CTH和ROS。本研究表明,IL - 6/STAT3/CTH轴在敏感和耐药的MCF - 7细胞之间的转化中起关键作用。意义声明:胱硫醚γ- 裂解酶(CTH)在MCF - 7细胞敏感和耐药表型的转化中起关键作用,并且依赖于白细胞介素 - 6(IL - 6)/信号转导及转录激活因子3(STAT3)信号轴。对CTH转硫途径或IL - 6/STAT3进行调节或补充蛋氨酸有利于逆转MCF - 7细胞的耐药性,这表明具有临床转化潜力。